CHO Pharma, Inc.(TW:6586)
NT$74.40+-2.00 (+0.27%)
TW:6586
CHO Pharma, Inc. financials statements
NT$74.40
At close:+-2.00 (+0.27%)
CHO Pharma, Inc. (6586) Ratios
CHO Pharma, Inc. Ratios
TW:6586's free cash flow for Q2 2026 was NT$-92.58M. For the 2026 fiscal year, TW:6586's free cash flow was decreased by NT$-1.24M and operating cash flow was NT$-91.34M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 19.47 | 20.81 | 24.93 | 6.39 | 10.06 |
| Quick Ratio | 19.47 | 20.81 | 24.93 | 6.39 | 10.06 |
| Cash Ratio | 0.48 | 0.19 | 1.92 | 2.99 | 5.84 |
| Solvency Ratio | -2.41 | -1.41 | -2.51 | -1.72 | -1.11 |
| Operating Cash Flow Ratio | -2.56 | -1.87 | -2.75 | -1.48 | -1.45 |
| Short-Term Operating Cash Flow Coverage | -19.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 2.01B | NT$ 2.28B | NT$ 2.53B | NT$ 905.75M | NT$ 1.19B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.05 | 1.04 | 1.12 | 1.09 |
| Debt Service Coverage Ratio | -19.95 | -273.42 | -3606.90 | -990.84 | -288.66 |
| Interest Coverage Ratio | -802.56 | -367.15 | -3493.48 | -1165.78 | -365.44 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.07 | 0.14 | 0.00 | 0.07 | 0.14 |
| Net Debt to EBITDA | 0.13 | -0.04 | 0.73 | 1.66 | 4.53 |
| Profitability Margins | |||||
| Gross Profit Margin | -1784.70% | 47.77% | 0.00% | 98.33% | 94.09% |
| EBIT Margin | -22770.16% | -5909.13% | 0.00% | -563486.67% | -5752.07% |
| EBITDA Margin | -20904.96% | -5185.73% | 0.00% | -497070.00% | -4657.31% |
| Operating Profit Margin | -22770.16% | -6963.49% | 0.00% | -584833.33% | -5896.11% |
| Pretax Profit Margin | -20265.97% | -5928.10% | 0.00% | -563988.33% | -5768.21% |
| Net Profit Margin | -20265.97% | -5928.10% | 0.00% | -563988.33% | -5768.21% |
| Continuous Operations Profit Margin | -20265.97% | -5928.10% | 0.00% | -563988.33% | -5768.21% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 89.00% | 85.13% | 113.79% | 96.44% | 97.83% |
| Return on Assets (ROA) | -11.27% | -7.37% | -9.92% | -21.12% | -10.87% |
| Return on Equity (ROE) | -11.77% | -7.72% | -10.29% | -23.69% | -11.81% |
| Return on Capital Employed (ROCE) | -13.23% | -9.02% | -9.03% | -24.48% | -11.96% |
| Return on Invested Capital (ROIC) | -13.15% | -8.97% | -9.03% | -24.28% | -11.86% |
| Return on Tangible Assets | -13.47% | -8.64% | -11.53% | -30.62% | -14.88% |
| Earnings Yield | -4.82% | -1.93% | -2.31% | -1.37% | -1.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.18 | 1.67 | 0.00 | 0.67 | 56.67 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.05 | 0.10 | 0.00 | 0.00 | 0.11 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2048.18 | 218.29 | 0.00 | 547.50 | 6.44 |
| Days of Sales Outstanding | 2048.18 | 218.29 | 0.00 | 547.50 | 6.44 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 2048.18 | 218.29 | 0.00 | 547.50 | 6.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.31 | -1.02 | -1.52 | -1.36 | -1.05 |
| Free Cash Flow Per Share | -1.35 | -1.04 | -1.53 | -1.41 | -1.07 |
| Dividend Paid and CapEx Coverage Ratio | -30.07 | -39.57 | -145.56 | -26.55 | -73.26 |
| Capital Expenditure Coverage Ratio | -30.07 | -39.57 | -145.56 | -26.55 | -73.26 |
| Operating Cash Flow Coverage Ratio | -19.16 | -7.52 | 0.00 | -21.33 | -7.57 |
| Operating Cash Flow to Sales Ratio | -195.37 | -60.72 | 0.00 | -4158.40 | -54.19 |
| Free Cash Flow Yield | -4.80% | -2.02% | -2.21% | -1.05% | -1.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -20.66 | -52.02 | -43.31 | -73.10 | -74.55 |
| Price-to-Sales (P/S) Ratio | 4202.45 | 3078.65 | 0.00 | 412383.72 | 4301.00 |
| Price-to-Book (P/B) Ratio | 2.44 | 4.01 | 4.46 | 17.32 | 8.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -20.82 | -49.45 | -45.23 | -95.57 | -78.30 |
| Price-to-Operating Cash Flow Ratio | -21.51 | -50.70 | -45.54 | -99.17 | -79.36 |
| Price-to-Earnings Growth (PEG) Ratio | -0.55 | 1.36 | 3.32 | -1.14 | 2.42 |
| Enterprise Value Multiple | -19.98 | -59.41 | -47.01 | -81.31 | -87.82 |
| Enterprise Value | 5.98B | 11.03B | 13.05B | 24.25B | 14.60B |
| EV to EBITDA | -19.98 | -59.41 | -47.01 | -81.31 | -87.82 |
| EV to Sales | 4176.25 | 3080.63 | 0.00 | 404151.04 | 4090.24 |
| EV to Free Cash Flow | -20.69 | -49.48 | -44.54 | -93.66 | -74.46 |
| EV to Operating Cash Flow | -21.38 | -50.73 | -44.84 | -97.19 | -75.48 |
| Tangible Book Value Per Share | 9.55 | 10.86 | 13.29 | 5.06 | 6.71 |
| Shareholders’ Equity Per Share | 11.51 | 12.84 | 15.55 | 7.77 | 9.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.02 | 0.00 | 0.00 | 0.02 |
| Net Income Per Share | -1.36 | -0.99 | -1.60 | -1.84 | -1.12 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.89 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 200.45 | 61.19 | 0.00 | 5434.95 | 54.20 |
| SG&A to Revenue | 9.40 | 8.92 | 0.00 | 414.37 | 5.70 |
| Stock-Based Compensation to Revenue | 3.52 | -4.00 | 0.00 | 366.52 | -3.88 |
| Income Quality | 0.96 | 1.02 | 0.95 | 0.74 | 0.94 |
Currency in TWD
